IMMUNITYBIO, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
IMMUNITYBIO, INC. (IBRX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 0.10% for the 12-month period ending 2020-12-31, per its 8-K/A filed 2021-04-22.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2021-04-22
- IMMUNITYBIO, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2018 was 0.10%, a 83.33% decline from fiscal 2017.
- IMMUNITYBIO, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2017 was 0.60%, a 53.85% decline from fiscal 2016.
- IMMUNITYBIO, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2016 was 1.30%, a 1200.00% increase from fiscal 2015.
- IMMUNITYBIO, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2015 was 0.10%, a 85.71% decline from fiscal 2014.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month as first filed |
|---|---|---|
| 2020-12-31 | 0.10% 8-K/A · filed 2021-04-22 | |
| 2019-12-31 | 0.10% 8-K/A · filed 2021-04-22 | 0.20% 10-K · filed 2020-03-25 |
| 2018-12-31 | 0.10% 10-K · filed 2021-03-04 | |
| 2017-12-31 | 0.60% 10-K · filed 2020-03-25 | |
| 2016-12-31 | 1.30% 10-K · filed 2019-03-13 | |
| 2015-12-31 | 0.10% 10-K · filed 2018-03-12 | |
| 2014-12-31 | 0.70% 10-K · filed 2017-03-15 | |
| 2013-12-31 | 0.00% 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |